Skip to main content Skip to section navigation Skip to footer
LIXTE-logo-web-horz-black-190
  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
✕
  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 21, 2022 8:30 am EDT

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

Jun 15, 2022 8:30 am EDT

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Apr 14, 2022 6:45 pm EDT

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 12, 2022 1:52 pm EDT

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 12, 2022 8:30 am EDT

LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

Mar 22, 2022 8:30 am EDT

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Mar 16, 2022 8:30 am EDT

LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference

Jan 12, 2022 8:30 am EST

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Jan 5, 2022 8:30 am EST

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Nov 22, 2021 9:25 am EST

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 12
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
Lixte Logo

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing innovative cancer therapies and oncology treatments using PP2A inhibition with LB-100.

CONTACT

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
Email: info@lixte.com

LIXTE Biotechnology Holdings, Inc.
is publicly traded as LIXT.

Privacy Policy | Terms of Use

  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
amazon behance bloglovin dribbble email facebook flickr github goodreads instagram linkedin medium meetup periscope phone pinterest reddit rss snapchat tiktok tripadvisor tumblr twitter vimeo whatsapp xing youtube
  • Facebook
  • LinkedIn
  • Twitter
© 2025 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. | Site by Third Eye Industries